Novus Biologicals Honored on the List of Colorado Companies to Watch
Novus Biologicals is one of fifty companies selected by the Colorado Office of Economic Development and International Trade as a Colorado Company to Watch
Thermo Fisher Scientific Inc., the world leader in serving science, and Novus Biologicals, LLC announced today the signing of a non-exclusive agreement giving Novus global rights to use Thermo Scientific DyLight® Fluorescent Dyes in combination with Novus’ extensive line of antibodies. Financial details of the arrangement were not disclosed.
NovActiveâ„¢ proteins are the first commercially available growth factors and cytokines produced in barley endosperm, a eukaryotic plant host. Unlike other growth factors and cytokines produced in bacterial or mammalian hosts, NovActiveâ„¢ products are free of serum carryover, proteases, pro-inflammatories, and bacterial/human/animal infectious agents. As barley endosperm is a eukaryote, our proteins display more natural folding and post-translational modification than those produced in a bacterial host.
Novus Biologicals, a Colorado based company supplying over 70,000 antibodies and related research products to the scientific community, is opening its first international office in Cambridge Science Park in Cambridge, UK. After an intensive search, Mark Long has been hired as the Divisional Manager of the new Novus Europe office. Mark acted as the Head of Marketing for Abcam plc for nearly ten years. During this time there, Mark gained extensive experience in developing and implementing global sales strategies and marketing campaigns.
The newly released OLLAS epitope tag and monoclonal antibody offer significant advantages over the other epitope tag/antibody combinations. The OLLAS tag has been demonstrated to allow full protein function whether used as an N-terminal, C-terminal or internal tag. In addition, the OLLA-2 monoclonal antibody has been demonstrated to be more than 100-fold more sensitive than similar antibodies to other commercially available tags.
Novus Biologicals introduces the new FasL-Strep Apoptosis Assay kits from IBA GmbH. A new patented fusion technology linking FasL with a “T4-foldon†globular protein provides for a superior bioactive, stable, well defined trimer. This Modified FasL is fused with a Strep tag making it ideal for apoptosis induction and detection. The advantages of the FasL-Strep are the defined trimeric structure, high stability, efficient apoptosis induction, and easy handling for detection, immobilization, and isolation via the strep-tag.
MaxPab® is a new collection of polyclonal antibodies generated from annotated, sequence verified full-length proteins. Each MaxPab® antibody is validated with a full-length human protein expressed from a mammalian transfected lysate, demonstrating high reactivity, sensitivity and specificity. In addition, MaxPab® antibody has the ability to recognize both linear and conformational protein epitopes for maximum antibody performance!
Beclin 1 is the first identified mammalian gene to mediate autophagy and also has tumor suppressor and antiviral function. Autophagy, a process of bulk protein degradation through an autophagosomic-lysosomal pathway, is important for differentiation, survival during nutrient deprivation, and normal growth control, and is often defective in tumor cells.
